CONTENTS

Section 1: Coronary Heart Disease 1

Critical Journal Review 1

1. Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function 1
2. Outcomes in Women Better with Newer Generation DES 4
3. When is Rotational Angiography Superior to Conventional Single-plane Angiography for Planning Coronary Angioplasty? 6
4. Effects of Optimism and Gratitude on Physical Activity, Biomarkers, and Readmissions After an Acute Coronary Syndrome The Gratitude Research in Acute Coronary Events Study (GRACE study) 9
5. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease 11
6. Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease—A Pairwise and Network Meta-Analysis 13
7. Effect of Supplemental Oxygen Exposure on Myocardial Injury in ST-elevation Myocardial Infarction 15
8. Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease 17
9. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction The ATLANTIC-H24 Analysis 20
10. Successful Recanalization of Native Coronary Chronic Total Occlusion Is Not Associated With Improved Long-Term Survival 22
11. Comparison of Early Versus Delayed Oral β-Blockers in Acute Coronary Syndromes and Effect on Outcomes 24
12. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI 25
13. Drug Filled Polymer Free Stent Non-inferior to Conventional Drug Eluting Stent First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study 28
14. Emergency Percutaneous Coronary Intervention in Post-Cardiac Arrest Patients without ST Segment Elevation Pattern: Insights from the PROCAT II Registry 31
15. A Novel Score Predictive of Technical Failure During Percutaneous Coronary Revascularization for Chronic Total Occlusions 33

16. PCI or CABG….or Both Together? Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease 36
17. Is Percutaneous Coronary Intervention (PCI) a Viable Option In Perioperative Myocardial Infarction (PMI)? Percutaneous Intervention for Myocardial Infarction after Noncardiac Surgery 38
18. Pharmacodynamics Effects of Switching From Prasugrel to Ticagrelor: Results of Prospective Randomized SWAP 3 Study 40
19. Early Invasive Treatment for NSTEMI-ACS Reduces Hospital Stay and Recurrent Ischemia But Not Death and MI: Timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndrome and clinical outcomes 42
20. Is Percutaneous Coronary Intervention Considered to be a Potential Alternative to Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis? Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease. 5-Year Outcomes of the PRECOMBAT Study 45
21. Is It Time for Percutaneous Coronary Intervention for all Lesions in STEMI? Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease. The CvLPRIT Trial 48
22. Does Operator Experience Play a Role in Outcomes after Left Main Percutaneous Coronary Intervention Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention 51
23. Does Percutaneous Coronary Intervention improve Outcomes in a patient with Multi-vessel Disease and Concurrent Chronic Total Occlusion? Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients with STEMI The EXPLORE Trial 53
24. Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG 55
25. “When You Encounter Ectasia in Primary PCI”: Risk Factors and Outcomes in Patients With Ectatic Infarct-related Artery who Underwent Primary Percutaneous Coronary Intervention After ST Elevated Myocardial Infarction 59
26. What is the Answer in Multivessel Disease? CABG or PCI? Long Term Mortality Revascularization In Nondiabetic Patients with Multivessel Disease 61
27. Early Angiography could reduce Bleeding Events in Patients with non ST Segment Elevation Acute Coronary Syndrome Bleeding events before coronary angiography in patients with non ST segment elevation Acute Coronary Syndrome 64
28. When is the Right Time? Surgery post Coronary Drug Eluting Stent Implantation: Risk Associated With Surgery With 12 Months After Coronary Drug-Eluting Stent Implantation 67

29. Is Aspiration Thrombectomy “Really” Associated with Increased Risk for Stroke? The Risk for Stroke With Aspiration Thrombectomy: Procedure or Patient Related? Insights From a Meta-Analysis 70
30. Faster Drug Absorption, More Prompt and Potent Antiplatelet Effects: The New Crushed Prasugrel: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention 72
31. Safety and Efficacy Benefits of DCS over BMS in Patients With High Risk Of Bleeding 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents 76
32. The EBC TWO Study (European Bifurcation Coronary TWO): A Randomized Comparison of Provisional T-Stenting Versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations 80
33. Is Coronary Artery Bypass Graft Surgery Associated with Better Outcomes as Compared to Percutaneous Coronary Intervention? Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in Treatment of Unprotected Left Main Stenosis (Noble): A Prospective, Randomised, Open-label, Non-inferiority Trial 82
34. The Evergreen Debate: PCI Versus Surgery in Unprotected Left Main CAD Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease 84
35. Left Internal Mammary Artery Versus Coronary Stents: Impact on Downstream Coronary Stenoses and Conduit Patency 89
36. Repeat Revascularization more common after Percutaneous Coronary Intervention than after Coronary Artery Bypass Grafting Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting The SYNTAX Trial at 5 Years 91
37. Biocompatible Durable Polymer Coated Des Non Inferior to Biodegradable Polymer Des Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients with Coronary Artery Disease 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial 93
38. Is there an ideal Level of Platelet P2Y12 Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention? “Window “ Analysis from the ADAPT-DES Study 96
39. Effect of Preoperative Aspirin Replacement With Enoxaparin in Patients Undergoing Primary Isolated on Pump CABG 99
40. Perioperative Cardiovascular Risk of Prior Coronary Stent Implantation Among Patients Undergoing Non Cardiac Surgery 103
41. A Randomized Comparison of Reservoir Based Polymer Free Amphilimus Eluting Stent Versus Everolimus Eluting Stent With Durable Polymer In Patients With Diabetes Mellitus 106
42. The Association of Previous Revascularization with In-hospital Outcomes in Acute Myocardial Infarction Patients 110

43. Post Hospital Outcomes of the Patients With Acute Myocardial Infarction With Cardiogenic Shock 113
44. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in The Pegasus-TIMI 54 Trial 115
45. Impact of Access Site on Bleeding and Ischemic Effects in Patients With Nstemi Treated With Prasugrel 118
46. Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug Elutng Stents 120
47. Refining Echo Techniques for Left Ventricular Thrombus Detection Post-Myocardial Infarction Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR 123

Cardiology Currents ***125***

48. Biodegradable Polymers versus Durable Polymers: Has the Jury Returned? 125
49. High Sensitivity Troponins: Opportunities and Challenges 128
50. When and Which Antiplatelet Drug Loading before PCI in Stable IHD? 130
51. Fractional Flow Reserve Computed Tomography—Ready for Prime Time? 132
52. Myocardial Viability Testing—Why and How? 134
53. Serendipity from Noncardiac Imaging 138
54. A Chronic Total Occlusion is Known by the Company it Keeps! 141
55. Deferring Stenting in Primary PCI—What is the Last Word? 143
56. Left Main Disease, Who's Baby is It Anyway? 146
57. Management of Stable Ischemic Heart Disease – Current Perspective 149
58. Dilemma–BMS or Des for Patients at High Bleeding Risk? 154
59. Dilemma–Non ST Elevation Myocardial Infarction: When to Intervene? 156
60. Bioresorbable Scaffolds for Management of Coronary Bifurcation Lesions—Feasible? 158

Section 2: Noncoronary Heart Disease **161**

Critical Journal Review 161

61. Causes of Death in Anticoagulated Patients With Atrial Fibrillation 161
62. Benefit of Vitamin K Antagonist Addition Anticoagulation Versus Antiplatelet or No Therapy In Patients Undergoing Bioprosthetic Valve Implantation: A Systematic Review and Meta-Analysis 165
63. Age is the Culprit! Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry 168

64. Importance of NOAC Optimum Dosing: Focus on ORBIT-AF II Registry Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. The ORBIT-AF II Registry 172
65. Is Percutaneous Mitral Valve Plication Effective in Management of Severely Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy 175
66. Oral anticoagulation or Aspirin—What is Better? Aspirin Instead of Oral Anticoagulants Prescription in Atrial Fibrillation Patients at Risk for Stroke 177
67. The Feminine Advantage: One Year Outcomes after TAVR Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. TVT Registry From 2011 to 2014 180
68. Feasibility Trial of Percutaneous Repair and Replacement Mitral Regurgitation Percutaneous Direct Annuloplasty. Lessons From an Early Feasibility Trial 184

Cardiology Currents 186

69. Clearing Patients with Severe Aortic Stenosis for Non cardiac Surgery 186
70. The Value of Calcium in a Stenotic Aortic Valve 189
71. Iron Therapy for Heart Failure—Intravenous or Oral? 191
72. Atrial Fibrillation in STEMI Poor Prognosis: Determinants of Prognosis in Atrial Fibrillation in Acute ST-Elevation Myocardial Infarction (STEMI) and Acute Coronary Syndrome (ACS)—Arrhythmia or Comorbidities? 193
73. Which New Oral Anticoagulant for Which Patient? 196

Section 3: Preventive Cardiology 199

Critical Journal Review 199

74. Morning Home Blood Pressure is a Strong Predictor of Coronary Artery Disease: The HONEST Study 199
75. Statins for Prevention of Cardiovascular Events in a Low-risk Population with Low Ankle Brachial Index 201
76. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention 202
77. The Association between Alcohol Abuse and Cardiac Disease 204
78. Troponin Concentration Change at 1 year is Associated with Future Coronary Risk Independent of Cholesterol Lowering: High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease 207
79. Influenza Vaccine for Prevention of MI: Influenza Vaccine as a Coronary Intervention for Prevention of Myocardial Infarction 210

80. Are they Related: Social Relationships and Coronary Heart Disease? Loneliness and Social Isolation as Risk Factors for Coronary Heart Disease and Stroke: Systematic Review and Meta-Analysis of Longitudinal Observational Studies 213
81. Tracking Plaque Regression with Statins on CCTA: Effects of Statin Therapy on Progression of Mild Noncalcified Coronary Plaque Assessed by Serial Coronary Computed Tomography Angiography: A Multicenter Prospective Study 216
82. Importance of Intensive BP Control in Older Patients: Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients 218
83. The Primary Drivers Of Changes In Preventive Medical And Lifestyle Practices Amongst People Presenting With Suspected Coronary Artery Disease: Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease 221
84. A New Weapon in the Prevention Armamentarium? Phosphodiesterase Type-5 Inhibitor Use in Type 2 Diabetes is Associated with a Reduction in All-cause Mortality 223
85. Pulse Pressure and Risk of Cardiovascular Events in Patients With Atherothrombosis 225

Cardiology Currents 228

86. Why Prevention is the Key to a Woman's Heart? 228
87. Statins for Primary Prevention – Widening the Net in "Low-risk" People. Narrowing it in "High-risk" People 231

Index